STIM logo

NEURONETICS INC

STIMNASDAQ
🏆 #3695 by market capEarnings Nov 4 · PreUS Equity
$2.26▲ $0.07 (+3.43%)
Market closed · at close
🔔
Track STIM
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.4%
7d▲ 8.4%
14d▲ 15.3%
30d▼ 3.4%
ytd▲ 63.8%
1y▼ 22.3%
🏦Market Cap
$172M
Small Cap
📈Revenue Growth (YoY)
39.6%
High Growth
📊Gross Margin
49.1%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
1.1x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$2.19 – $2.28
52-Week Range
$0.80 – $3.44
Volume (shares)
26,379
Avg Volume (shares)
—
Shares Outstanding
76.2M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$149M
Last Q Revenue
$42M
P/E Ratio
—
P/S Ratio
1.1x
EPS (TTM)
$-0.44
Dividend Yield
—
Dilution (1yr)
+87.5%
STIM logo

NEURONETICS INC

STIM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$149M▲ +99.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
48.5%▼ −33.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$31M▼ −9.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$21M▼ −34.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
68.8M▲ +87.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$56M▲ +$7M YoY
StockOtter · stockotter.space

About NEURONETICS INC

Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
10 analysts
Strong Buy3
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.